The Latest Analyst Ratings for Y-mAbs Therapeutics
Y-mAbs Therapeutics (NASDAQ:YMAB) has observed the following analyst ratings within the last quarter: Bullish Somewhat Bullish Indifferent Somewhat…
Morgan Stanley Downgrades Y-mAbs Therapeutics to Underweight
Morgan Stanley analyst Michael Ulz downgrades Y-mAbs Therapeutics (NASDAQ:YMAB) from Equal-Weight to Underweight.
Y-mAbs Announces Partnership Regarding Early Access Program For DANYELZA In Europe
Y-mAbs Therapeutics, Inc. (the "Company" or "Y-mAbs") (NASDAQ:YMAB) a commercial-stage biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic
Analyst Ratings for Y-mAbs Therapeutics
Within the last quarter, Y-mAbs Therapeutics (NASDAQ:YMAB) has observed the following analyst ratings: Bullish Somewhat Bullish Indifferent Somewhat…
Y-mAbs Announces Complete Response Letter For Omburtamab Biologics License Application
Y-mAbs Therapeutics, Inc. (the "Company" or "Y-mAbs") (NASDAQ:YMAB) a commercial-stage biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic
Looking Into Y-mAbs Therapeutics’s Recent Short Interest
Y-mAbs Therapeutics's (NASDAQ:YMAB) short percent of float has fallen 16.88% since its last report. The company recently reported that it has 3.08 million shares sold short, which is 8.47% of all regular shares that are available for trading.
Why Party City Holdco Shares Tumbled Over 40%; Here Are 98 Biggest Movers From Yesterday
Gainers
Unique Fabricating, Inc. (NYSE: UFAB) jumped 56.3% to close at $0.8205 on Tuesday. Unique Fabricating posted a Q3 loss of $0.90 per share after the closing bell on Tuesday.
Why TaskUs Shares Are Trading Higher By 37%? Here Are 77 Stocks Moving In Tuesday’s Mid-Day Session
Gainers
IceCure Medical Ltd (NASDAQ: ICCM) shares jumped 39.4% to $1.4529 after the company announced a payment assignment from the Centers for Medicare & Medicaid Services for the ProSense breast cancer cryoablation procedures.
Provention Bio’s Second Try, Apellis’s Eye Disorder Drug Review, 3 Adcom Verdicts And More: November’s Key PDUFA Catalysts Biotech Investors Must Know
Editor's note: This story has been corrected to reflect that the FDA deferred action on Amicus Therapeutics' Biologics License Application.